A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders
Phase of Trial: Phase III
Latest Information Update: 18 Jun 2019
Price : $35 *
At a glance
- Drugs Nabiximols (Primary)
- Indications Gilles de la Tourette's syndrome; Tic disorders
- Focus Therapeutic Use
- Acronyms CANNA-TICS
- 14 Jun 2019 Planned End Date changed from 1 May 2019 to 1 Oct 2020.
- 14 Jun 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Sep 2020.
- 29 Mar 2018 Status changed from not yet recruiting to recruiting.